Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Auditor change
Credit agrmnt [a]
Quarterly results
Appointed director
CC transcript
Inv. presentation
|
|
Option Care Health, Inc. (BIOS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/27/2023 |
8-K
| Quarterly results |
| 05/03/2023 |
8-K
| Quarterly results |
| 07/27/2022 |
8-K
| Quarterly results |
| 04/28/2022 |
8-K
| Quarterly results |
| 11/04/2021 |
8-K
| Quarterly results |
| 08/03/2021 |
8-K
| Quarterly results |
| 05/06/2021 |
8-K
| Quarterly results |
| 11/03/2020 |
8-K
| Quarterly results |
| 08/04/2020 |
8-K
| Quarterly results |
| 05/07/2020 |
8-K
| Quarterly results |
| 11/06/2019 |
8-K
| Quarterly results |
| 07/30/2019 |
8-K
| Quarterly results |
| 05/02/2019 |
8-K
| Quarterly results|
Docs:
|
"BioScrip Reports First Quarter 2019 Financial Results DENVER, CO, May 2, 2019 – BioScrip, Inc. , the largest independent national provider of infusion and home care management solutions, today announced its first quarter 2019 financial results. First Quarter 2019 Highlights · Net revenue of $179.0 million, up 6.2% compared to $168.6 million in the first quarter of 2018. · Net revenue up 7.8% on a billing day rate basis; there was one less billing day in the first quarter of 2019 as compared to the first quarter of 2018. · Net loss from continuing operations of $10.3 million, compared to $13.0 million in the prior year quarter. · Adjusted EBITDA of $7.1 million, up 25.6% compared to $5.6 million in the prior year quarter, despite $4.5 million of increased bad deb..." |
|
| 11/06/2018 |
8-K
| Quarterly results|
Docs:
|
"BioScrip Reports Third Quarter 2018 Financial Results DENVER, CO, November 6, 2018 – BioScrip, Inc. , the largest independent national provider of infusion and home care management solutions, today announced its third quarter 2018 financial results. Third Quarter 2018 Highlights · Net revenue of $181.0 million, compared to $198.7 million in the third quarter of 2017. Excluding exited UHC therapy line revenue from the prior year quarter, net revenue increased approximately 5%. · Net loss from continuing operations of $8.1 million, a $5.0 million improvement compared to the prior year quarter. · Adjusted EBITDA of $16.4 million, 25% above the prior year quarter, driven by a 510 basis point improvement in gross profit margin, reflecting ASC 606 pro forma adjustments. &mid..." |
|
| 08/07/2018 |
8-K
| Quarterly results|
Docs:
|
"BioScrip Reports Second Quarter 2018 Financial Results DENVER, CO, August 7, 2018 – BioScrip, Inc. , the largest independent national provider of infusion and home care management solutions, today announced its second quarter 2018 financial results. Second Quarter 2018 Highlights · Net revenue of $175.8 million, including core product mix of 75.1%, compared to 73.6% in the prior year quarter, reflecting the impact of the implementation of ASC 606 * , which resulted in the recognition of amounts previously reported as bad debt expense as a reduction to revenue · Net loss from continuing operations of $15.1 million, a $14.0 million improvement compared to the prior year quarter · Adjusted EBITDA of $11.4 million, 14% above the prior year quarter, driven by a 510 basis po..." |
|
| 05/10/2018 |
8-K
| Quarterly results|
Docs:
|
"BioScrip Reports First Quarter 2018 Financial Results DENVER, CO, May 10, 2018 – BioScrip, Inc. , the largest independent national provider of infusion and home care management solutions, today announced its first quarter 2018 financial results. First Quarter 2018 Highlights · Net revenue of $168.6 million, including core product mix of 75.4%, compared to 71.9% in the prior year quarter, including the impact of the implementation of ASC 606 * in the first quarter of 2018, which resulted in the recognition of amounts previously reported as bad debt expense as a reduction to revenue · Net revenues, primarily for antibiotics therapies that carry higher than average gross profit margins, were negatively impacted by an estimated $2.5 million during the first quarter of 2018, due t..." |
|
| 11/02/2017 |
8-K/A
| Quarterly results|
Docs:
|
"BioScrip Reports Third Quarter 2017 Financial Results - Net revenue of $198.7 million, including core product mix of 75.0%, compared to 65.8% in the prior year - Net revenue and adjusted EBITDA reduced $10.0 million and $3.0 million, respectively, due to sales disruption from Hurricane Irma, Hurricane Harvey, and completion of the UnitedHealthcare contract transition - Net loss from continuing operations of $12.4 million, compared to $11.1 million in the prior year - Adjusted EBITDA of $13.0 million, more than three times the prior year, driven by a 590 basis point improvement in gross profit margin and a $4.8 million reduction in operating expenses - Operating cash use of $0.3 million, reflecting $15.8 million of interest, including $8.9 million of bi-annual bond interest payments, and $1..." |
|
| 11/02/2017 |
8-K
| Quarterly results|
Docs:
|
"BioScrip Reports Third Quarter 2017 Financial Results - Net revenue of $198.7 million, including core product mix of 75.0%, compared to 65.8% in the prior year - Net revenue and adjusted EBITDA reduced $10.0 million and $3.0 million, respectively, due to sales disruption from Hurricane Irma, Hurricane Harvey, and completion of the UnitedHealthcare contract transition - Net loss from continuing operations of $12.4 million, compared to $11.1 million in the prior year - Adjusted EBITDA of $13.0 million, more than three times the prior year, driven by a 590 basis point improvement in gross profit margin and a $4.8 million reduction in operating expenses - Operating cash use of $0.3 million, reflecting $15.8 million of interest, including $8.9 million of bi-annual bond interest payments, and $1..." |
|
| 08/08/2017 |
8-K/A
| Quarterly results |
| 08/08/2017 |
8-K
| Quarterly results |
| 05/04/2017 |
8-K
| Form 8-K - Current report |
| 05/05/2016 |
8-K
| Quarterly results |
| 03/02/2016 |
8-K
| Quarterly results |
| 11/04/2015 |
8-K
| Quarterly results |
| 08/10/2015 |
8-K
| Quarterly results |
| 05/07/2015 |
8-K
| Quarterly results |
| 03/02/2015 |
8-K
| Quarterly results, Credit agreement amendment |
| 11/05/2014 |
8-K
| Quarterly results |
| 08/06/2014 |
8-K
| Quarterly results |
| 05/09/2014 |
8-K
| Quarterly results |
| 02/26/2014 |
8-K
| Quarterly results |
| 11/06/2013 |
8-K
| Form 8-K - Current report |
| 08/07/2013 |
8-K
| Form 8-K - Current report |
| 05/08/2013 |
8-K
| Form 8-K - Current report |
|
|
|